Post-COVID-19 pulmonary fibrosis: A case series and review of literature
The most common lung problem faced by a post-COVID patient is lung fibrosis. Clinical recovery is generally complete in mild-to-moderately severe COVID-19 cases but a small proportion of patients with severe disease may go on to develop lung fibrosis. Patient groups at the highest risk to develop lu...
Main Authors: | Deependra K Rai, Subhash Kumar, Nishant Sahay |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Journal of Family Medicine and Primary Care |
Subjects: | |
Online Access: | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2021;volume=10;issue=5;spage=2028;epage=2031;aulast=Rai |
Similar Items
-
Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
by: Soroush Seifirad, et al.
Published: (2021-01-01) -
Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment
by: Elena Cojocaru, et al.
Published: (2023-12-01) -
Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
by: Yuzo Suzuki, et al.
Published: (2021-07-01) -
Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers
by: Aurelio Perez-Favila, et al.
Published: (2024-01-01) -
Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
by: Sachin Chaudhary, et al.
Published: (2020-09-01)